These findings were further corroborated by whole transcriptome analysis of 510 low versus high ADAM2 expressing TCGA LUAD cases where analysis of the 50 cancer hallmark pathways identified suppression of IFNγ, TNFα via NFκβ, IL6/JAK/STAT3 signaling and complement pathways in ADAM2hi-expressing tumors. This evidence concerns the gene ADAM2 and cancer.